(27-T) Hospitalization Rates, 30-day Readmissions, Workdays Missed, and Length of Stay for Darolutamide in Metastatic Sensitive Hormone Sensitive Metastatic Cancer (mHSPC) from the ARASENS Study
Tuesday, June 13, 2023
12:15 PM - 1:30 PM
Co-Author(s): Alicia Morgans, Neal Shore, Emma Tyas, Fernando Rodriguez Santamaria